Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
"We are focused on optimizing the potential for success in the promising late-stage development program of REL-1017 for the adjunctive treatment of major depressive disorder," said Sergio Traversa, Relmada's Chief Executive Officer. "The amended protocol for ongoing Study 302, is now being implemented and enrollment is progressing, with trial completion anticipated in the first half of 2024. For the new planned Study 304, we have finalized site selection and solidified a rigorous patient eligibility process."
"We are optimistic about the protocol and trial design improvements we have made. Based on data generated to date, we believe we have been able to identify those clinical sites that were better able to control placebo response, and those that understand the importance of enrolling appropriate subjects with documented diagnoses and treatment histories. We have increased our own internal oversight of the subject eligibility process with the build-out of an internal clinical development team led by our Chief Medical Officer, Dr. Cedric O'Gorman, who has previously run positive registrational trials in MDD. Moreover, we are sufficiently funded to execute our plans to reach data readouts from both Phase 3 trials in 2024."
- Implemented the amended protocol for ongoing Reliance II (Study 302), a Phase 3 trial of REL-1017 for the adjunctive treatment of MDD
- Completed protocol and finalized site selection for Study 304, the new planned Phase 3 trial of REL-1017 for the adjunctive treatment of MDD
- Conclusion of Reliance OLS (Study 310), a long-term, open-label study of REL-1017 in MDD
- Two late-breaking posters accepted for presentation at the upcoming 2023 American Society of Clinical Psychopharmacology Meeting
- Complete enrollment in ongoing Reliance II (Study 302), which is planned to enroll approximately 300 patients, in the first half of 2024
- Initiate new Study 304 in mid-2023, with a planned enrollment of approximately 300 patients, with completion anticipated in the second half of 2024
- Announce results from the Reliance OLS (Study 310) in 2023
- Research and development expense for the three months ended March 31, 2023, totaled
$15.9 million $25.0 million
- General and administrative expense for the three months ended March 31, 2023, totaled
$12.3 million $13.3 million
- Net loss for the three months ended March 31, 2023, was
$26.3 million $0.87 $39.7 million $1.40
- Net cash used in operating activities for the three months ended March 31, 2023, totaled
$16.5 million $19.4 million
- As of March 31, 2023, the Company had cash, cash equivalents, and short-term investments of approximately
$132.4 million $148.3 million
Thursday, May 11 at 4:30 PM ET
Toll Free: | 833 470 1428 |
International: | https://www.netroadshow.com/events/global-numbers?confId=50778 |
Conference ID: | 224217 |
Webcast: |
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). The ongoing Reliance Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of clinical trial results to demonstrate clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
tim@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
Relmada Therapeutics, Inc. Condensed Consolidated Balance Sheets | ||||||||
As of | ||||||||
March 31, | As of | |||||||
2023 | December 31, | |||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 28,894,360 | $ | 5,395,905 | ||||
Short-term investments | 103,547,634 | 142,926,781 | ||||||
Other receivables | - | 512,432 | ||||||
Prepaid expenses | 3,089,580 | 4,035,186 | ||||||
Total current assets | 135,531,574 | 152,870,304 | ||||||
Other assets | 34,875 | 34,875 | ||||||
Total assets | $ | 135,566,449 | $ | 152,905,179 | ||||
Commitments and Contingencies (See Note 6) | ||||||||
Liabilities and Stockholders' Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 4,421,965 | $ | 5,261,936 | ||||
Accrued expenses | 5,675,292 | 7,206,941 | ||||||
Total current liabilities | 10,097,257 | 12,468,877 | ||||||
Total liabilities | 10,097,257 | 12,468,877 | ||||||
Stockholders' Equity: | ||||||||
Class A convertible preferred stock, | - | - | ||||||
Common stock, | 30,099 | 30,099 | ||||||
Additional paid-in capital | 613,871,604 | 602,517,138 | ||||||
Accumulated deficit | (488,432,511) | (462,110,935) | ||||||
Total stockholders' equity | 125,469,192 | 140,436,302 | ||||||
Total liabilities and stockholders' equity | $ | 135,566,449 | $ | 152,905,179 | ||||
Relmada Therapeutics, Inc. Condensed Consolidated Statements of Operations (Unaudited) | ||||||||
Three months ended | ||||||||
March 31, | ||||||||
2023 | 2022 | |||||||
Operating expenses: | ||||||||
Research and development | $ | 15,861,010 | $ | 25,012,853 | ||||
General and administrative | 12,292,599 | 13,284,570 | ||||||
Total operating expenses | 28,153,609 | 38,297,423 | ||||||
Loss from operations | (28,153,609) | (38,297,423) | ||||||
Other income (expenses): | ||||||||
Interest/investment income, net | 1,207,631 | 329,949 | ||||||
Realized loss on short-term investments | (666,708) | (15,022) | ||||||
Unrealized gain (loss) on short-term investments | 1,291,110 | (1,763,287) | ||||||
Total other income (expenses) | 1,832,033 | (1,448,360) | ||||||
Net loss | $ | (26,321,576) | $ | (39,745,783) | ||||
Loss per common share – basic and diluted | $ | (0.87) | $ | (1.40) | ||||
Weighted average number of common shares outstanding – basic and diluted | 30,099,203 | 28,392,601 | ||||||
Relmada Therapeutics, Inc. Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) | ||||||||||||||||||||
Three months ended March 31, 2023 | ||||||||||||||||||||
Common Stock | Additional | Accumulated | ||||||||||||||||||
Shares | Par Value | Capital | Deficit | Total | ||||||||||||||||
Balance - December 31, 2022 | 30,099,203 | $ | 30,099 | $ | 602,517,138 | $ | (462,110,935) | $ | 140,436,302 | |||||||||||
Stock based compensation | - | - | 11,354,466 | - | 11,354,466 | |||||||||||||||
Net loss | - | - | - | (26,321,576) | (26,321,576) | |||||||||||||||
Balance – March 31, 2023 | 30,099,203 | $ | 30,099 | $ | 613,871,604 | $ | (488,432,511) | $ | 125,469,192 | |||||||||||
Three months ended March 31, 2022 | ||||||||||||||||||||
Common Stock | Additional | Accumulated | ||||||||||||||||||
Shares | Par Value | Capital | Deficit | Total | ||||||||||||||||
Balance - December 31, 2021 | 27,740,147 | $ | 27,740 | $ | 513,304,258 | $ | (305,067,112) | $ | 208,264,886 | |||||||||||
Stock based compensation | - | - | 11,930,681 | - | 11,930,681 | |||||||||||||||
ATM offering, net | 1,609,343 | 1,610 | 29,581,932 | - | 29,583,542 | |||||||||||||||
Warrant exercised for cash | 33,334 | 33 | 299,973 | - | 300,006 | |||||||||||||||
Options exercised for cash | 20,000 | 20 | 64,780 | - | 64,800 | |||||||||||||||
Net loss | - | - | - | (39,745,783) | (39,745,783) | |||||||||||||||
Balance - March 31, 2022 | 29,402,824 | $ | 29,403 | $ | 555,181,624 | $ | (344,812,895) | $ | 210,398,132 | |||||||||||
Relmada Therapeutics, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) | ||||||||
Three months ended | ||||||||
March 31, | ||||||||
2023 | 2022 | |||||||
Cash flows from operating activities | ||||||||
Net loss | $ | (26,321,576) | $ | (39,745,783) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation expense | - | - | ||||||
Stock-based compensation | 11,354,466 | 11,930,681 | ||||||
Realized loss on short-term investments | 666,708 | 15,022 | ||||||
Unrealized (gain) loss on short-term investments | (1,291,110) | 1,763,287 | ||||||
Change in operating assets and liabilities: | ||||||||
Lease payment receivable | - | 20,923 | ||||||
Other receivables | 512,432 | - | ||||||
Prepaid expenses | 945,606 | 6,237,575 | ||||||
Accounts payable | (839,971) | (522,353) | ||||||
Accrued expenses | (1,531,649) | 870,905 | ||||||
Net cash used in operating activities | (16,505,094) | (19,429,743) | ||||||
Cash flows from investing activities | ||||||||
Purchase of short-term investments | (34,767,287) | (25,915,957) | ||||||
Sale of short-term investments | 74,770,836 | 15,888,289 | ||||||
Net cash provided by (used in) investing activities | 40,003,549 | (10,027,668) | ||||||
Cash flows from financing activities | ||||||||
Proceeds from issuance of common stock | - | 29,583,542 | ||||||
Proceeds from options exercised for common stock | - | 64,800 | ||||||
Proceeds from warrants exercised for common stock | - | 300,006 | ||||||
Net cash provided by financing activities | - | 29,948,348 | ||||||
Net increase in cash and cash equivalents | 23,498,455 | 490,937 | ||||||
Cash and cash equivalents at beginning of the period | 5,395,905 | 44,443,439 | ||||||
Cash and cash equivalents at end of the period | $ | 28,894,360 | $ | 44,934,376 | ||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-provides-corporate-update-and-reports-first-quarter-2023-financial-results-301822760.html
SOURCE Relmada Therapeutics, Inc.
